Posted inCardiology Internal Medicine news
Higher Lipoprotein(a) Marks Greater Coronary Risk Without Prior MI or Stroke, While Evolocumab Delivers Similar Relative Benefit and Larger Absolute Gains
In VESALIUS-CV, elevated baseline Lp(a) independently predicted major coronary events, especially MI, in patients without prior MI or stroke. Evolocumab reduced relative risk similarly across Lp(a) levels, with numerically greater absolute benefit in those with higher Lp(a).